Prevalence of Hepatitis C Virus Subgenotypes 1a and 1b in Japanese Patients: Ultra-Deep Sequencing Analysis of HCV NS5B Genotype-Specific Region
Carregando...
Citações na Scopus
31
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
WU, Shuang
KANDA, Tatsuo
NAKAMOTO, Shingo
JIANG, Xia
MIYAMURA, Tatsuo
NAKATANI, Sueli M.
TAKAHASHI-NAKAGUCHI, Azusa
GONOI, Tohru
YOKOSUKA, Osamu
Citação
PLOS ONE, v.8, n.9, article ID e73615, 7p, 2013
Resumo
Background: Hepatitis C virus (HCV) subgenotypes 1a and 1b have different impacts on the treatment response to peginterferon plus ribavirin with direct-acting antivirals (DAAs) against patients infected with HCV genotype 1, as the emergence rates of resistance mutations are different between these two subgenotypes. In Japan, almost all of HCV genotype 1 belongs to subgenotype 1b. Methods and Findings: To determine HCV subgenotype 1a or 1b in Japanese patients infected with HCV genotype 1, real-time PCR-based method and Sanger method were used for the HCV NS5B region. HCV subgenotypes were determined in 90% by real-time PCR-based method. We also analyzed the specific probe regions for HCV subgenotypes 1a and 1b using ultra-deep sequencing, and uncovered mutations that could not be revealed using direct-sequencing by Sanger method. We estimated the prevalence of HCV subgenotype 1a as 1.2-2.5% of HCV genotype 1 patients in Japan. Conclusions: Although real-time PCR-based HCV subgenotyping method seems fair for differentiating HCV subgenotypes 1a and 1b, it may not be sufficient for clinical practice. Ultra-deep sequencing is useful for revealing the resistant strain(s) of HCV before DAA treatment as well as mixed infection with different genotypes or subgenotypes of HCV.
Palavras-chave
Referências
- Akuta N, 2013, J MED VIROL, V85, P1028, DOI 10.1002/jmv.23579
- Bacon BR, 2011, NEW ENGL J MED, V364, P1207, DOI 10.1056/NEJMoa1009482
- Brownell J, 2013, CLIN CANCER RES, V19, P1347, DOI 10.1158/1078-0432.CCR-12-0928
- Chayama K, 2012, HEPATOLOGY, V55, P742, DOI 10.1002/hep.24724
- Chevaliez S, 2012, GASTROENTEROLOGY, V142, P1303, DOI 10.1053/j.gastro.2012.02.027
- Di Bisceglie AM, 1997, HEPATOLOGY S1, V26, p34S
- Eriksson N, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000074
- Hayashi K, 2012, J MED VIROL, V84, P438, DOI 10.1002/jmv.23207
- Kanda T, 2010, HEPATOL INT, V4, P548, DOI 10.1007/s12072-010-9193-3
- Kanda Tatsuo, 2013, Clin Transl Med, V2, P9, DOI 10.1186/2001-1326-2-9
- Kieffer TL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034372
- Lok AS, 2012, NEW ENGL J MED, V366, P216, DOI 10.1056/NEJMoa1104430
- Nakano T, 2004, J INFECT DIS, V190, P1098, DOI 10.1086/422606
- Nakatani SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010150
- Nasu A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024907
- Ninomiya M, 2012, J CLIN MICROBIOL, V50, P857, DOI 10.1128/JCM.05715-11
- SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547
- Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819
- Soriano V, 2011, J ANTIMICROB CHEMOTH, V66, P1673, DOI 10.1093/jac/dkr215
- Stedman CAM, 2013, J GASTROEN HEPATOL, V28, P38, DOI 10.1111/jgh.12028
- TAKADA N, 1993, J HEPATOL, V17, P277, DOI 10.1016/S0168-8278(05)80205-3
- TANAKA T, 1994, HEPATOLOGY, V19, P1347, DOI 10.1016/0270-9139(94)90226-7
- Thomas LB, 2012, ANN CLIN LAB SCI, V42, P355
- Thomas XV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041191
- TSUKIYAMAKOHARA K, 1993, VIROLOGY, V192, P430, DOI 10.1006/viro.1993.1058
- Vispo E, 2012, J CLIN VIROL, V55, P58, DOI 10.1016/j.jcv.2012.05.012
- Wang CL, 2007, GENOME RES, V17, P1195, DOI 10.1101/gr.6468307
- Wu SA, 2011, J HEPATOL, V54, P19, DOI 10.1016/j.jhep.2010.06.018